A novel mechanism of action of the fumagillin analog, TNP-470, in the B16F10 murine melanoma cell line

Anti-Cancer Drugs

Volumn 16, Issue 8, 2005, Pages 817-823

  Okrój, Marcin ^a   Kamysz, Wojciech ^a   Slominska, Ewa M ^a   Mysliwski, Andrzej ^a   Bigda, Jacek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Angiogenesis; Flow cytometry; Melanoma; Reactive oxygen species; TNP 470

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT; DICHLORODIHYDROFLUORESCEIN DIACETATE; FUMAGILLOL CHLOROACETYLCARBAMATE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETYLCYSTEINE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELLS, CULTURED; CYCLOHEXANES; ENDOTHELIAL CELLS; HELA CELLS; HUMANS; KIDNEY; MELANOMA, EXPERIMENTAL; MICE; REACTIVE OXYGEN SPECIES; SESQUITERPENES;

EID: 24044502878     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000172835.60142.a5     Document Type: Article

References (43)

1. Harris AL, Talks KL. Current status of antiangiogenic factors. Br J Haematol 2000; 109:477-489.
2. Brown PD. Matrix metalloproteinase inhibitors. Breast Cancer Res Treat 1998; 52:125-136.
3. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348:555-557.
4. Yamamoto T, Sudo K, Fujita T. Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res 1994; 14:1-3.
5. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA 2000; 97:6427-6432.
6. Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci USA 2000; 97:12782-12787.
7. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69:212-216.
8. Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, et al. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994; 54:3407-3412.
9. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997; 94:6099-6103.
10. Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci USA 1998; 95:15183-15188.
11. Koyama H, Nishizawa Y, Hosoi M, Fukamoto S, Kogawa K, Shioi A, et al. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-l. Possible involvement of cyclin-dependent kinase 2. Circ Res 1996; 79:757-764.
12. Fan YF, Huang ZH, Nie J. Effect of TNP-470 on rat vascular smooth muscle cell growth and cell cycle. Di Yi Jun Yi Da Xue Xue Bao 2002; 22:325-329.
13. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993; 53:2566-2570.
14. Sedlakova O, Sedlak J, Hunakova L, Jakubikova J, Duraj J, Sulikova M, et al. Angiogenesis inhibitor TNP-470: cytotoxic effects on human neoplastic cell lines. Neoplasma 1999; 46:283-289.
15. Okrój M, Dobrzanska-Paprocka Z, Rolka K, Bigda J. In vitro and in vivo analyses of the biological activity of RGD peptides towards Ab Bomirski melanoma. Cell Mol Biol Lett 2003; 8:873-884.
16. Riddles PW, Blakeley RL, Zerner B. Reassessment of Ellman's reagent. Methods Enzymol 1983; 91:49-60.
17. Smit NP, Van der Meulen H, Koerten HK, Kolb RM, Mommaas AM, Lentjes EG. Melanogenesis in cultured melanocytes can be substantially influenced by L-tyrosine and L-cysteine. J Invest Dermatol 1997; 109:796-800.
18. Slominski A, Moellmann G, Kuklinska E, Bomirski A, Pawelek J. Positive regulation of melanin pigmentation by two key substrates of the melanogenic pathway, L-tyrosine and L-dopa. J Cell Sci 1988; 89:287-296.
19. Turk BE, Griffith EC, Wolf S, Biemann K, Chang YH, Liu JO. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 1999; 6:823-833.
20. Gong J, Traganos F, Darzynkiewicz Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 1994; 218:314-319.
21. Vanags DM, Porn-Ares MI, Coppola S, Burgess DH, Orrenius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J Biol Chem 1996; 271:31075-31085.
22. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lossota P, et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13:795-808.
23. Walker NI, Harmon BV, Gobe GC, Kerr JF. Patterns of cell death. Methods Achiev Exp Pathol 1988; 13:18-54.
24. Leist M, Single B, Naumann H, Fava E, Simon B, Kuhnle S, et al. Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis. Exp Cell Res 1999; 249:396-403.
25. Stocker P, Lesgards JF, Vidal N, Chalier F, Prost M. ESR study of a biological assay on whole blood: antioxidant efficiency of various vitamins. Biochim Biophys Acta 2003; 1621:1-8.
26. Sonee M, Martens JR, Evers MR, Mukherjee SK. The effect of tertiary butylhydroperoxide and nicotinamide on human cortical neurons. Neurotoxicology 2003; 24:443-448.
27. Kallmann B, Burkart V, Kroncke KD, Kolb-Bachofen V, Kolb H. Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide. Life Sci 1992; 51:671-678.
28. Lukienko PI, Mel'nichenko NG, Zverinskii IV, Zabrodskaya SV. Antioxidant properties of thiamine. Bull Exp Biol Med 2000; 130:874-876.
29. Miura K, Ishii T, Sugita Y, Bannai S. Cystine uptake and glutathione level in endothelial cells exposed to oxidative stress. Am J Physiol 1992; 262:C50-C58.
30. Slyshenkov VS, Shevalye AA, Liopo AV, Wojtczak L. Protective role of L-methionine against free radical damage of rat brain synaptosomes. Acta Biochim Pol 2002; 49:907-916.
31. Repine JE, Fox RB, Berger EM. Hydrogen peroxide kills Staphylococcus aureus by reacting with staphylococcal iron to form hydroxyl radical. J Biol Chem 1981; 256:7094-7096.
32. Soszynski M, Bartosz G. Decrease in accessible thiols as an index of oxidative damage to membrane proteins. Free Rad Biol Med 1997; 23:463-469.
33. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Rad Biol Med 1989; 6:593-597.
34. De Flora S, Rossi GA, De Flora A. Metabolic, desmutagenic and anticarcinogenic effects of N-acetylcysteine. Respiration 1986; 50(suppl 1):43-49.
35. Kaminski M, Masaoka M, Karbowski M, Kedzior J, Nishizawa Y, Usukura J, et al. Ultrastructural basis for the transition of cell death mode from apoptosis to necrosis in menadione-treated osteosarcoma 143B cells. J Electron Microsc (Tokyo) 2003; 52:313-325.
36. Kaminski M, Karbowski M, Miyazaki Y, Kedzior J, Spodnik JH, Gil A, et al. Co-existence of apoptotic and necrotic features within one single cell as a result of menadione treatment. Folia Morphol (Warsz) 2002; 61:217-220.
37. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 1995; 92:7162-7166.
38. Mysliwski A, Koszalka P, Bigda J, Szmit E. Complete remission of Bomirski Ab amelanotic melanoma in hamsters treated with the angiogenesis inhibitor TNP-470. Neoplasma 2002; 49:319-322.
39. Mysliwski A, Kubasik-Juraniec J, Koszalka P, Szmit E. The effect of angiogenesis inhibitor TNP-470 on the blood vessels of the lungs, kidneys and livers of treated hamsters. Folia Morphol (Warsz) 2004; 63:5-9.
40. Kruger EA, Figg WD. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin Invest Drugs 2000; 9:1383-1396.
41. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, et al. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999; 5:1989-1995.
42. Metodiewa D, Koska C. Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview. Neurotox Res 2000; 1:197-233.
43. Rao AV, Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci 2002; 5:291-309.